0001447362-21-000213.txt : 20210907
0001447362-21-000213.hdr.sgml : 20210907
20210907172611
ACCESSION NUMBER: 0001447362-21-000213
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210902
FILED AS OF DATE: 20210907
DATE AS OF CHANGE: 20210907
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Spiess Bernhard E.
CENTRAL INDEX KEY: 0001782994
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38984
FILM NUMBER: 211240119
MAIL ADDRESS:
STREET 1: C/O CASTLE BIOSCIENCES, INC.
STREET 2: 820 S. FRIENDSWOOD DRIVE, SUITE 201
CITY: FRIENDSWOOD
STATE: TX
ZIP: 77546
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CASTLE BIOSCIENCES INC
CENTRAL INDEX KEY: 0001447362
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 770701774
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 505 S FRIENDSWOOD DRIVE
STREET 2: SUITE 401
CITY: FRIENDSWOOD
STATE: TX
ZIP: 77546
BUSINESS PHONE: 866-788-9007
MAIL ADDRESS:
STREET 1: 505 S FRIENDSWOOD DRIVE
STREET 2: SUITE 401
CITY: FRIENDSWOOD
STATE: TX
ZIP: 77546
4
1
wf-form4_163104995353264.xml
FORM 4
X0306
4
2021-09-02
0
0001447362
CASTLE BIOSCIENCES INC
CSTL
0001782994
Spiess Bernhard E.
C/O CASTLE BIOSCIENCES, INC.
505 S. FRIENDSWOOD DRIVE, STE. 401
FRIENDSWOOD
TX
77546
0
1
0
0
Chief Business Officer
Common Stock
2021-09-02
4
M
0
8989
1.92
A
22551
D
Common Stock
2021-09-02
4
M
0
6412
2.39
A
28963
D
Common Stock
2021-09-02
4
S
0
8038
75.24
D
20925
D
Common Stock
2021-09-02
4
S
0
5889
76.14
D
15036
D
Common Stock
2021-09-02
4
S
0
1474
77.29
D
13562
D
Stock option (right to buy)
1.92
2021-09-02
4
M
0
8989
0
D
2026-05-23
Common Stock
8989.0
5889
D
Stock option (right to buy)
2.39
2021-09-02
4
M
0
6412
0
D
2028-05-09
Common Stock
6412.0
2304
D
These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 19, 2021.
This transaction was executed in multiple trades at prices ranging from $74.59 to $75.58, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $75.60 to $76.45, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $76.70 to $77.63, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
25% of the 169,592 shares originally subject to the option vested on May 2, 2017, and the remaining shares vested in 36 equal monthly installments thereafter.
25% of the 12,305 shares originally subject to the option vested on May 10, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.
/s/ Greg Acosta, Attorney-in-fact
2021-09-07